All In Biotech

Drug Trial Radar · NCT03032380

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Last checked: Nov 20, 2026Latest source record: Nov 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Oct 24, 2017

Primary completion

Feb 26, 2019

Study completion Apr 1, 2019

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Jan 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by Gram-negative pathogens.

Conditions

  • Healthcare-associated Pneumonia (HCAP)
  • Hospital Acquired Pneumonia (HAP)
  • Ventilator Associated Pneumonia (VAP)

Interventions

  • CefiderocolDrug

    2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)

  • MeropenemDrug

    2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)

  • LinezolidDrug

    600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause Mortality Rate at Day 14Time frame: From first dose of study drug to Day 14

Locations

119 sites in 19 countries. Site status is shown where the registry gives one.

  • Shionogi Research Site

    New Haven, Connecticut

  • Shionogi Research Site

    DeLand, Florida

  • Shionogi Research Site

    Chicago, Illinois

  • Shionogi Research Site

    Council Bluffs, Iowa

  • Shionogi Research Site

    Louisville, Kentucky

  • Shionogi Research Site

    Baton Rouge, Louisiana

  • Shionogi Research Site

    Shreveport, Louisiana

  • Shionogi Research Site

    Annapolis, Maryland

  • Shionogi Research Site

    Detroit, Michigan

  • Shionogi Research Site

    St Louis, Missouri

  • Shionogi Research Site

    Cleveland, Ohio

  • Shionogi Research Site

    Columbus, Ohio

  • Shionogi Research Site

    Bethlehem, Pennsylvania

  • Shionogi Research Site

    Philadelphia, Pennsylvania

  • Shionogi Research Site

    Salt Lake City, Utah

  • Shionogi Research Site

    Brussels, Belgium

  • Shionogi Research Site

    Brussels, Belgium

  • Shionogi Research Site

    Halifax, Nova Scotia, Canada

  • Shionogi Research Site

    Kingston, Ontario, Canada

  • Shionogi Research Site

    Brno, Czechia

  • Shionogi Research Site

    Hradec Králové, Czechia

  • Shionogi Research Site

    Kolín, Czechia

  • Shionogi Research Site

    Kyjov, Czechia

  • Shionogi Research Site

    Ostrava-Poruba, Czechia

  • Shionogi Research Site

    Prague, Czechia

  • Shionogi Research Site

    Příbram, Czechia

  • Shionogi Research Site

    Kohtla-Järve, Estonia

  • Shionogi Research Site

    Pärnu, Estonia

  • Shionogi Research Site

    Tallinn, Estonia

  • Shionogi Research Site

    Tartu, Estonia

  • Shionogi Research Site

    Angers, France

  • Shionogi Research Site

    Argenteuil, France

  • Shionogi Research Site

    Bron, France

  • Shionogi Research Site

    LaRoche-sur-Yon, France

  • Shionogi Research Site

    Lyon, France

  • Shionogi Research Site

    Nice, France

  • Shionogi Research Site

    Paris, France

  • Shionogi Research Site

    Batumi, Georgia

  • Shionogi Research Site

    Kutaisi, Georgia

  • Shionogi Research Site

    Kutaisi, Georgia

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.